A novel therapeutic regimen based on the constrained-disorder principles may improve the response to dimethyl fumarate in multiple sclerosis: Findings from an exploratory feasibility open-label clinical trial
A novel therapeutic regimen based on the constrained-disorder principles may improve the response to dimethyl fumarate in multiple sclerosis: Findings from an exploratory feasibility open-label clinical trial. // IBRO Neuroscience Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2667242126001466?dgcid=rss_sd_all
A novel therapeutic regimen based on the constrained-disorder principles may improve the response to dimethyl fumarate in multiple sclerosis: Findings from an exploratory feasibility open-label clinical trial. IBRO Neuroscience Reports. https://www.sciencedirect.com/science/article/pii/S2667242126001466?dgcid=rss_sd_all
“A novel therapeutic regimen based on the constrained-disorder principles may improve the response to dimethyl fumarate in multiple sclerosis: Findings from an exploratory feasibility open-label clinical trial.” IBRO Neuroscience Reports.
@article{article9124,
title = {A novel therapeutic regimen based on the constrained-disorder principles may improve the response to dimethyl fumarate in multiple sclerosis: Findings from an exploratory feasibility open-label clinical trial},
journal = {IBRO Neuroscience Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2667242126001466?dgcid=rss_sd_all}
}